Balentine LLC Anavex Life Sciences Corp. Transaction History

Balentine LLC

$2.54 Billion
Q3 2024

A detailed history of Balentine LLC transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Balentine LLC holds 20,200 shares of AVXL stock, worth $174,326. This represents 0.0% of its overall portfolio holdings.

Number of Shares

20,200

Holding current value

$174,326

% of portfolio

0.0%

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 30, 2024	BUY	$4.11 - $7.04 $83,022 - $142,208	20,200 New	20,200 $114,000
Q1 2018 May 16, 2018	SELL	$2.32 - $3.44 $649 - $963	-280 Closed	0 $0
Q3 2017 Nov 15, 2017	BUY	$3.42 - $4.87 $957 - $1,363	280	280 $1,000

Others Institutions Holding AVXL

# of Institutions

155

Shares Held

27.3M

Call Options Held

515K

Put Options Held

838K

Black Rock Inc. New York, NY

6.39M
Shares

$55.2 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

4.74M
Shares

$40.9 Million
0.0% of portfolio
State Street Corp Boston, MA

3.07M
Shares

$26.5 Million
0.0% of portfolio
Geode Capital Management, LLC Boston, MA

1.88M
Shares

$16.3 Million
0.0% of portfolio
Wealthgarden F.S. LLC El Segundo, CA

910K
Shares

$7.86 Million
0.32% of portfolio

View Full List

About ANAVEX LIFE SCIENCES CORP.

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $673M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

More about AVXL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Balentine LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balentine LLC with notifications on news.

Account